HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is ...

NEW YORK – Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than ... with CRISPR Therapeutics for SCD and TDT, called Casgevy (exagamglogene autotemcel) ...

2024 saw Vertex Pharmaceuticals generate its first ... Casgevy ® (“exa-cel” or exagamglogene autotemcel), which it co-developed with CRISPR Therapeutics—$2 million during the third quarter ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, announces that in accordance with the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

The hefty tariffs President-elect Trump has pledged to levy on U.S. imports could impact the price and availability of pharmaceutical drugs. Trump has floated 25 percent tariffs on imports from ...